BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10755359)

  • 1. The clinical value of the ratio of free prostate specific antigen to total prostate specific antigen.
    Dalva I; Akan H; Yildiz O; Telli C; Bingol N
    Int Urol Nephrol; 1999; 31(5):675-80. PubMed ID: 10755359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of free PSA/total PSA ratio in the diagnosis of prostatic cancer in symptomatic patients with PSA levels ranging from 2.5 to 20 ng/ml].
    Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Leal Hernández F; Bielsa Carrillo A; García Burgos J; Subirá Ríos D
    Actas Urol Esp; 2000 Jan; 24(1):24-30. PubMed ID: 10746371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Usefulness of free/total PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from prostatic cancer].
    Mosquera Madera J; Pinto Sierra I; Enguix Armada A; Sahagún Argüello JL
    Actas Urol Esp; 2001 Oct; 25(9):651-5. PubMed ID: 11765549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
    Lein M; Koenig F; Jung K; McGovern FJ; Skates SJ; Schnorr D; Loening SA
    Br J Urol; 1998 Aug; 82(2):231-6. PubMed ID: 9722758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
    Hugosson J; Aus G; Bergdahl S; Fernlund P; Frösing R; Lodding P; Pihl CG; Lilja H
    BJU Int; 2003 Dec; 92 Suppl 2():39-43. PubMed ID: 14983953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early diagnosis of prostate cancer using free/total prostate-specific antigen ratio with population-based screening data].
    Zhang L; Ji G; Li X; Wang W; Gao H; Pan Y; Wang H; Masaaki K; Zhao X
    Zhonghua Nan Ke Xue; 2004 Aug; 10(8):582-5. PubMed ID: 15362518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
    Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
    BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
    Iqbal N; Chaughtai N
    J Pak Med Assoc; 2005 Aug; 55(8):318-20. PubMed ID: 16164156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.